Mani Kalaivani
Research Subjects
Mani Kalaivani has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bharathi M. Purohit
Division of Public Health Dentistry, Centre for Dental Education and Research, All India Institute of Medical Sciences (AIIMS), New Delhi, India
1 shared publication - Jatin Lonyal
Department of Oral Medicine and Radiology, Centre for Dental Education and Research, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Ruchika Gupta
Division of Cytopathology, ICMR-National Institute of Cancer Prevention and Research, Noida, India
1 shared publication - Savita Yadav
Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Shalini R. Gupta
Oral Medicine and Radiology All India Institute of Medical Sciences New Delhi India
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Comparative evaluation of the effect of topical Photodynamic therapy versus topical Calcipotriol on the clinical and molecular characteristics of Oral leukoplasia: a randomized clinical trial (Preprint)
BACKGROUND Oral cancer is one of the most common cancers in India. It is usually preceded by Oral potentially malignant disorders like Oral leucoplakia (OL) in nearly two thirds of the cases. OL has high prevalence and malignant transformation rates (1.1% - 40.8%). There are no universal protocols for management in OL ranging from preventive, conservative, medical and surgical interventions. They have limitations and high recurrence rates requiring regular follow up. Removal of pathological lesions are believed to reduce the risk of malignant transformation in OL. Surgical methods have high morbidity and recurrence rates. Non –invasive methods like Photodynamic therapy (PDT) and topical Calcipotriol need to be explored. They would be preferred as they are cheaper, convenient, safe with better patient acceptability. They have the advantage of repeatability with minimum morbidity and damage to adjacent normal tissues. OBJECTIVE The primary objective is to compare the effect of 2.5% Toluidine blue mediated topical PDT and topical Calcipotriol (0.005%) on clinical response after completion of treatment at 4 weeks from baseline during management of OL. Secondary objectives are to assess lesion thickness, size, impact on oral health, salivary biomarkers, adverse events and recurrence. METHODS An open label prospective, single- centre, randomized clinical trial where Group A (n=83) will receive 4 sessions of Toluidine blue mediated photodynamic therapy (Fluence 15J/cm2) and Group B (n=83) will receive twice daily topical application of Calcipotriol (0.005%) over a period of 4 weeks as an adjunct to Conventional usual preventive care. The clinical response (complete/ partial/ none), lesion thickness/ whiteness, lesion size /area, Oral Health Impact Profile-14 scores, adverse events and recurrence rates will be compared with baseline at 4 weeks and 12 weeks after completion of therapy. Sterile PVA ophthalmic sponges will be used to evaluate salivary molecular markers ( IL6, TNF-α, PCNA, Survivin VEGF) from treatment site of lesion at baseline and 4 weeks after completion of treatment by ELISA. The data will be analysed statistically using Intention to treat and as per protocol analysis at significance levels of p<0.05. RESULTS This study has been approved by Institute Ethics Committee at all India Institute of Medical sciences New Delhi ( AIIMSA5773/13.02.2026, RP-29/2026)). Subject recruitment with follow up is expected to be completed by February 2027. Data analysis, manuscript preparation and submission for publication are expected to be completed May 2027. CONCLUSIONS This novel RCT will generate evidence whether topical Toluidine blue mediated PDT or topical Calcipotriol is effective in improving clinical response, lesion thickness/ whiteness, lesion size and oral health quality of life in OL. Adverse events if any and recurrence rates or malignant transformation will also help in assessment of safety of the protocol. The molecular markers will help to monitor and determine prognosis of the lesions following treatment. CLINICALTRIAL ClinicalTrials.gov PRS_ PDT CACI NCT07453472
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessComparative evaluation of the effect of topical Photodynamic therapy versus topical Calcipotriol on the clinical and molecular characteristics of Oral leukoplasia: a randomized clinical trial (Preprint)
BACKGROUND Oral cancer is one of the most common cancers in India. It is usually preceded by Oral potentially malignant disorders like Oral leucoplakia (OL) in nearly two thirds of the cases. OL has high prevalence and malignant transformation rates (1.1% - 40.8%). There are no universal protocols for management in OL ranging from preventive, conservative, medical and surgical interventions. They have limitations and high recurrence rates requiring regular follow up. Removal of pathological lesions are believed to reduce the risk of malignant transformation in OL. Surgical methods have high morbidity and recurrence rates. Non –invasive methods like Photodynamic therapy (PDT) and topical Calcipotriol need to be explored. They would be preferred as they are cheaper, convenient, safe with better patient acceptability. They have the advantage of repeatability with minimum morbidity and damage to adjacent normal tissues. OBJECTIVE The primary objective is to compare the effect of 2.5% Toluidine blue mediated topical PDT and topical Calcipotriol (0.005%) on clinical response after completion of treatment at 4 weeks from baseline during management of OL. Secondary objectives are to assess lesion thickness, size, impact on oral health, salivary biomarkers, adverse events and recurrence. METHODS An open label prospective, single- centre, randomized clinical trial where Group A (n=83) will receive 4 sessions of Toluidine blue mediated photodynamic therapy (Fluence 15J/cm2) and Group B (n=83) will receive twice daily topical application of Calcipotriol (0.005%) over a period of 4 weeks as an adjunct to Conventional usual preventive care. The clinical response (complete/ partial/ none), lesion thickness/ whiteness, lesion size /area, Oral Health Impact Profile-14 scores, adverse events and recurrence rates will be compared with baseline at 4 weeks and 12 weeks after completion of therapy. Sterile PVA ophthalmic sponges will be used to evaluate salivary molecular markers ( IL6, TNF-α, PCNA, Survivin VEGF) from treatment site of lesion at baseline and 4 weeks after completion of treatment by ELISA. The data will be analysed statistically using Intention to treat and as per protocol analysis at significance levels of p<0.05. RESULTS This study has been approved by Institute Ethics Committee at all India Institute of Medical sciences New Delhi ( AIIMSA5773/13.02.2026, RP-29/2026)). Subject recruitment with follow up is expected to be completed by February 2027. Data analysis, manuscript preparation and submission for publication are expected to be completed May 2027. CONCLUSIONS This novel RCT will generate evidence whether topical Toluidine blue mediated PDT or topical Calcipotriol is effective in improving clinical response, lesion thickness/ whiteness, lesion size and oral health quality of life in OL. Adverse events if any and recurrence rates or malignant transformation will also help in assessment of safety of the protocol. The molecular markers will help to monitor and determine prognosis of the lesions following treatment. CLINICALTRIAL ClinicalTrials.gov PRS_ PDT CACI NCT07453472